达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.01.010

摘要/Abstract

摘要： 目的研究在达诺瑞韦基础上联合长效α-干扰素治疗基因3型慢性丙型肝炎(CHC)患者的临床疗效。方法 2017年10月～2019年5月我院收治的132例基因3型CHC患者,其中66例(对照组)接受聚乙二醇干扰素α-2a联合利巴韦林治疗24周,另66例(观察组)接受聚乙二醇干扰素α-2a和利巴韦林治疗的基础上,加用利托那韦和达诺瑞韦联合治疗12周。所有患者随访24周。结果在治疗2 w、4 w和12 w末,观察组病毒学应答率分别为90.9%、97.0%和100.0%,显著高于对照组的66.7%、75.8%和81.8%(P＜0.05);在治疗结束后24 w随访时,观察组持续病毒学应答率(SVR)为92.4%,显著高于对照组的74.2%(P＜0.05);在治疗12 w末,两组外周血白细胞计数、血小板计数和血红蛋白水平变化无统计学差异(P＞0.05),两组不良反应发生率比较差异也无统计学意义(P＞0.05)。结论应用利托那韦和达诺瑞韦联合标准治疗方案治疗基因3型CHC患者临床疗效确切,安全性较好,值得进一步观察。

关键词: 慢性丙型肝炎, 达诺瑞韦, 利托那韦, 聚乙二醇干扰素α-2a, 利巴韦林, 治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C (CHC). Methods 132 patients with genotype 3 infected CHC were admitted to our hospital between October 2017 and May 2019, and 66 patients were treated with peginterferon-2a and ribavirin for 24 weeks, and another 66 patients were treated with ritonavir and danorevir at base of standardized therapy for 12 weeks. All patients were followed-up for 24 weeks. Results At the end of 2 week, 4 week and 12 week treatment, the virological response rates in the combination group were 90.9%, 97.0% and 100.0%, respectively, significantly higher than 66.7%, 75.8% and 81.8% in standardized therapy-treated group (P<0.05); at the end of 24 week of follow-up after treatment, the sustained virological response (SVR) in the combination group was 92.4%, significantly higher than 74.2% in the control group (P<0.05); there were no statistically significant differences in white blood cell counts, platelet counts and hemoglobin levels in the two groups (P>0.05) and there wereno significant differences in the incidences of adverse reactions between the two groups (P>0.05).Conclusion The application of ritonavir and danorevir at base of standardized therapy in the treatment of patients with CHC and genotype 3 infection is efficacious and safe, which warrants further investigation.

Key words: Hepatitis C, Danorevir, Ritonavir, Pegylated interferon α-2a, Ribavirin, Therapy

杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.

Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C[J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.

参考文献

[1] 李威, 吴亚男, 奚琳琳,等. 基于医院大数据评估丙型肝炎病毒感染率. 中华肝脏病杂志, 2018, 26(6):426-428.
[2] Chadha S, Sharma U, Chaudhary A , et al. Molecular epidemiological analysis of three hepatitis C virus outbreaks in Jammu and Kashmir State, India. J Med Microbiol, 2016, 65(8):804-813.
[3] Tovo PA, Calitri C, Scolfaro C , et al. Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol, 2016, 22(4):1382-1392.
[4] Megahed A , Salem N , Fathy A , et al. Pegylated interferonα/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. World J Pediatr, 2017, 13(4):346-352.
[5] 黄建荣, 张文宏. 以达诺瑞韦为基础的抗病毒方案在慢性丙型肝炎治疗中的临床研究结果解读. 中华传染病杂志, 2018, 36(10):594-598.
[6] 中华医学会肝病学分会和感染病学分会.《丙型肝炎防治指南》2015年更新版.实用肝脏病杂志,2016,19(4):ⅠⅩ-ⅩⅩⅤⅠ.
[7] Ramamurthy N , Marchi E , Ansari MA , et al. Impact of IFNL4 genotype on interferon-stimulated gene expression during DAA therapy for hepatitis C.Hepatology, 2018, 68(3):859-871.
[8] Oh IS , Won JW , Kim HJ , et al. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.Korean J Intern Med, 2017, 32(6):1010-1017.
[9] 张艳芳, 李用国, 兰英华. 比较西甲匹韦与特拉匹韦联合聚乙二醇干扰素及利巴韦林的三联方案治疗慢性丙型肝炎基因1型患者的meta分析. 中华传染病杂志, 2018, 36(8):473-479.
[10] Znoyko OO, Dudina KR, Kozina AN , et al. Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2. Ter Arkh, 2016, 88(5):84-85.
[11] Jiménez-Pérez M, González-Grande R, Espaa Contreras P, et al. Treatment of chronic hepatitis C with direct-acting antivirals: the role of resistance. World J Gastroenterol, 2016, 22(29):6573-6581.
[12] 魏来. 达诺瑞韦及其联合PR方案治疗慢性丙型肝炎研究进展. 中华临床感染病杂志, 2018, 11(2):84-89.
[13] Everson G, Cooper C, Hézode C, et al. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int, 2015, 35(1):108-119.
[14] Turnes J, Domínguez-Hernández R2, Casado M. Value and innovation of direct-acting antivirals: Long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig, 2017, 109(12):809-817.
[15] Cholankeril G , Li AA , Yoo ER , et al. Direct-acting antiviral therapy and improvement in graft survival of hepatitis C liver transplant recipients. Transplantation, 2017, 101(12):349-354.
[16] Tkachenko LI , Maleev VV , Sannikova IV , et al. Use of a regional registry of chronic hepatitis patients to optimize antiviral therapy. Ter Arkh, 2015, 87(8):58-66.
[17] Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C.J Hepatol, 2016, 64(4):763-765.
[18] Shimada M , Nakamura N , Endo T , et al. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. BMC Nephrol, 2017, 18(1):109-114.
[19] Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol, 2019, 27(19):30699-307003.
[20] Medeiros T, Salviato CM, do Rosário NF, et al. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm, 2017, 39(6):1304-1311.